JNJ · News · 20261105N
RYBREVANT Head And Neck Expansion
JOHNSON & JOHNSON · 2026-11-05 · Importance 47 · Surprise 60 · In source text
The U.S. Food and Drug Administration granted accelerated approval to Johnson & Johnson’s Rybrevant Faspro for advanced head and neck squamous cell carcinoma. The approval covers patients whose disease progressed after chemotherapy and immunotherapy, addressing a cancer with limited treatment options. In clinical trial data cited in the report, 42% of treated patients experienced tumor shrinkage or disappearance.
Key facts
- The FDA granted accelerated approval to Johnson & Johnson's Rybrevant Faspro for advanced head and neck squamous cell carcinoma in patients whose disease progressed after chemotherapy and immunotherapy. source
- Clinical trial data showed that 42% of patients treated with Rybrevant Faspro experienced tumor shrinkage or disappearance. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The FDA granted accelerated approval to Johnson & Johnson's Rybrevant Faspro for advanced head and neck squamous cell carcinoma in… |